fenofibrate has been researched along with Liver Dysfunction in 8 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with fenofibrate attenuated AKI and associated hepatic dysfunction." | 5.62 | Fenofibrate attenuates ischemia reperfusion-induced acute kidney injury and associated liver dysfunction in rats. ( Kaur, J; Kaur, T; Pathak, D; Sharma, AK; Singh, AP; Yadav, HN, 2021) |
| " In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes." | 5.34 | Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. ( Cai, G; Du, L; Nie, Y; Xie, W; Zhang, Y, 2007) |
| "An increased risk for adverse events was observed with gemfibrozil relative to fenofibrate, predominantly driven by an increased rate of rhabdomyolysis." | 3.72 | Risk of adverse events with fibrates. ( Alsheikh-Ali, AA; Karas, RH; Kuvin, JT, 2004) |
| "Treatment with fenofibrate attenuated AKI and associated hepatic dysfunction." | 1.62 | Fenofibrate attenuates ischemia reperfusion-induced acute kidney injury and associated liver dysfunction in rats. ( Kaur, J; Kaur, T; Pathak, D; Sharma, AK; Singh, AP; Yadav, HN, 2021) |
| "The healthy male Wistar rats fed high fat diet were treated with fenofibrate (80 mg/kg per day) alone, allicin (60 mg/kg per day) alone and a lower dosage of combined therapy (allicin 20 mg/kg per day and fenofibrate 30 mg/kg per day) respectively for 8 weeks." | 1.36 | The effect of combination therapy of allicin and fenofibrate on high fat diet-induced vascular endothelium dysfunction and liver damage in rats. ( Li, W; Qiao, X; Qin, S; Song, G; Wang, D; Zuo, C, 2010) |
| " We reviewed gemfibrozil- and fenofibrate-associated adverse event reports (AERs) submitted to the US Food and Drug Administration over a 5-year period." | 1.35 | Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. ( Alsheikh-Ali, AA; Holoshitz, N; Karas, RH, 2008) |
| " In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes." | 1.34 | Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard. ( Cai, G; Du, L; Nie, Y; Xie, W; Zhang, Y, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaur, J | 2 |
| Kaur, T | 1 |
| Sharma, AK | 1 |
| Yadav, HN | 1 |
| Pathak, D | 1 |
| Singh, AP | 1 |
| He, Y | 1 |
| Qin, MZ | 1 |
| Chen, YW | 1 |
| Tazuke, Y | 1 |
| Teitelbaum, DH | 1 |
| Li, W | 1 |
| Wang, D | 1 |
| Song, G | 1 |
| Zuo, C | 1 |
| Qiao, X | 1 |
| Qin, S | 1 |
| Wierzbicki, AS | 1 |
| Mikhailidis, DP | 1 |
| Wray, R | 1 |
| Alsheikh-Ali, AA | 2 |
| Kuvin, JT | 1 |
| Karas, RH | 2 |
| Xie, W | 1 |
| Nie, Y | 1 |
| Du, L | 1 |
| Zhang, Y | 1 |
| Cai, G | 1 |
| Holoshitz, N | 1 |
1 review available for fenofibrate and Liver Dysfunction
| Article | Year |
|---|---|
Drug treatment of combined hyperlipidemia.
Topics: Acute Disease; Clofibric Acid; Diabetes Mellitus, Type 2; Female; Fenofibrate; Humans; Hydroxymethyl | 2001 |
7 other studies available for fenofibrate and Liver Dysfunction
| Article | Year |
|---|---|
Fenofibrate attenuates ischemia reperfusion-induced acute kidney injury and associated liver dysfunction in rats.
Topics: Acute Kidney Injury; Animals; Biomarkers; Fenofibrate; Liver Diseases; Male; Nitric Oxide Synthase T | 2021 |
Liver injury caused by fenofibrate within 48 h after first administration: a case report.
Topics: Chemical and Drug Induced Liver Injury; Fenofibrate; Humans; Liver Diseases; Male; Middle Aged | 2021 |
Alteration of canalicular transporters in a mouse model of total parenteral nutrition.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2009 |
The effect of combination therapy of allicin and fenofibrate on high fat diet-induced vascular endothelium dysfunction and liver damage in rats.
Topics: Animals; Dietary Fats; Disulfides; Endothelium, Vascular; Fenofibrate; Hypolipidemic Agents; Liver; | 2010 |
Risk of adverse events with fibrates.
Topics: Aged; Chemical and Drug Induced Liver Injury; Female; Fenofibrate; Gemfibrozil; Humans; Hyperlipidem | 2004 |
Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard.
Topics: Animals; Antioxidants; Ascorbic Acid; Blood Glucose; Chemical and Drug Induced Liver Injury; Cholest | 2007 |
Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Databases, Factual; | 2008 |